

■ MMIS cells

Human MMIS cells were isolated from the peripheral blood of a patient with a IgA lambda myeloma.

■ Tumour growth *in vivo*

The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.

The mice bearing MMIS tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.




Figure 1: Tumour growth curve of the MMIS cells as xenograft
Mean ± SEM (n=4; take rate 100%)

■ Standard-Of-Care Drug Responses

daratumumab 15 mg/kg qw → Response




Figure 2: Effect of daratumumab treatment on RPMI 8226 tumour growth
Mean ± SEM (n=4 per group; take rate 100%)

A MMIS model fully resistant to daratumumab, developed *in vivo* without genetic modifications, are available at Antineo.